Seeking Alpha
11 Nov 2025, 18:24 UTC · 43w ago
Verdict
Headline takes no side. We score IOVA −0.80 across four claims.
Our read: bearish.
IOVA score
−0.80
More negative than 86% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
4 claims · scored −1 bearish … +1 bullish
Iovance Biotherapeutics faces ongoing risk of share dilution.
More negative than 98% of claims this week
Q3 revenue of $68 million missed analyst estimates.
More negative than 86% of claims this week
Continue reading
5 related stories
The company's cash runway has been extended to Q2 2027.
More positive than 66% of claims this week
Gross margin showed modest improvement, reaching 29.6%.
More positive than 55% of claims this week
Which stocks this story touches
More negative than 86% of ticker scores this week
The company is rated as a Sell due to revenue misses, dilution risks, and execution issues.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1h ago
Price reaction
Expected −0.80Actual +262.9%
Price is moving against the score
209 sessions since publication. $8.60 vs $2.37 close before publication (Nov 10). Not market-adjusted.
IOVA chart →
